Gho Jennifer W-M, Ip Wai-Ki, Chan Kathy Y-Y, Law Priscilla T-Y, Lai Paul B-S, Wong Nathalie
Li Ka-Shing Institute of Health Sciences, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Cancer Res. 2008 Aug 15;68(16):6743-51. doi: 10.1158/0008-5472.CAN-07-6469.
Transcription factors represent an important class of genes that play key roles in controlling cellular proliferation, cell cycle modulation, and attractive targets for cancer therapy. Here, we report on the novel finding of common ATF5 down-regulations in hepatocellular carcinoma (HCC), a highly malignant tumor with a dismal clinical course. Array-based mapping in HCC highlighted a high and consistent incidence of transcription factor ATF5 repressions on regional chr.19q13. By quantitative reverse transcription-PCR, profound down-regulations of ATF5 were further suggested in 78% of HCC tumors (60 of 77 cases) compared to their adjacent nontumoral liver (P = 0.0004). Restoration of ATF5 expression in 3 nonexpressing HCC cell lines demonstrated a consistent growth inhibitory effect (P < 0.029) but minimal induction on cellular apoptosis. Subsequent flow cytometric investigations revealed a G(2)-M cell cycle arrest in HCC cells that were ectopically transfected with ATF5 (P < 0.002). The differential expressed genes from the functional effects of ATF5 were examined by array profiling. Over a hundred genes were identified, among which ID1 contains the ATF/CREB target binding sequences within its promoter region. An inverse relationship between ATF5 expressions with ID1 transcriptions was verified in HCC (P = 0.019), and a direct interaction of ATF5 on the promoter of ID1 was further demonstrated from electromobility shift assay. Examination of causal events underlying the silencing of ATF5 in HCC suggested copy number losses, promoter hypermethylation, histone deacetylation, and DNA mutations to be the likely inactivating mechanisms. In conclusion, our finding supports a tumor suppressive role for ATF5 in HCC, and highlighted ID1 as a potential downstream target.
转录因子是一类重要的基因,在控制细胞增殖、细胞周期调节中发挥关键作用,也是癌症治疗的有吸引力的靶点。在此,我们报告在肝细胞癌(HCC)中发现常见的ATF5下调这一新发现,HCC是一种临床病程不佳的高度恶性肿瘤。基于阵列的HCC图谱显示转录因子ATF5在19号染色体q13区域的抑制发生率高且一致。通过定量逆转录PCR,与相邻的非肿瘤肝脏相比,78%的HCC肿瘤(77例中的60例)中ATF5进一步显著下调(P = 0.0004)。在3个不表达ATF5的HCC细胞系中恢复ATF5表达显示出一致的生长抑制作用(P < 0.029),但对细胞凋亡的诱导作用最小。随后的流式细胞术研究显示,用ATF5异位转染的HCC细胞出现G(2)-M期细胞周期阻滞(P < 0.002)。通过阵列分析检查了ATF5功能效应的差异表达基因。鉴定出了一百多个基因,其中ID1在其启动子区域包含ATF/CREB靶结合序列。在HCC中验证了ATF5表达与ID1转录之间的负相关关系(P = 0.019),并且通过电泳迁移率变动分析进一步证明了ATF5与ID1启动子的直接相互作用。对HCC中ATF5沉默的潜在因果事件的研究表明,拷贝数缺失、启动子高甲基化、组蛋白去乙酰化和DNA突变可能是其失活机制。总之,我们的发现支持ATF5在HCC中具有肿瘤抑制作用,并突出了ID1作为潜在的下游靶点。